Charles River Laboratories (CRL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Charles River Laboratories.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 232.50 $ — 92% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 0.3% failed
- More than 10% revenue growth is expected for the coming year 1.9% failed
- Share count grows by less than 3% a year -1.1% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 12.1% failed
- Gross margin at 40% or higher and without meaningful erosion 30.5% failed
- Goodwill from acquisitions does not grow faster than revenue 38.7% passed
- Net debt below twice EBITDA 6.9 x EBITDA failed
- Operating cash flow covers the profits of the last three years 1,816 m passed
- Return on capital at 15% or higher, or up versus two years ago 8.4% failed
- Insiders hold at least 10% or are net buyers 0.6% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 1.7% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 19
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 11.11 | 10.94 – 11.32 | 3,850 | 8.0% | 16 |
| 12/31/2027 | 12.33 | 11.65 – 13.76 | 3,921 | 11.0% | 16 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 2.72 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -4.22 | -216.40 | 1,003 | -1.10 | -21.50 | 159 | 84 |
| 2025: Q1 | 0.50 | -61.40 | 984 | -2.70 | 2.60 | 172 | 112 |
| 2025: Q2 | 1.06 | -38.90 | 1,032 | 0.60 | 5.10 | 205 | 169 |
| 2025: Q3 | 1.10 | -17.30 | 1,005 | -0.50 | 5.40 | 214 | 178 |
| 2025: Q4 | -5.62 | – | 994 | -0.80 | -27.80 | 148 | 59 |
| 2026: Q1 | -0.30 | -160.50 | 996 | 1.20 | -1.50 | 41 | -15 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,681 | 238 | 155 | 3.23 | 298 | 837 | 2,712 |
| 2017 | 1,858 | 288 | 123 | 2.54 | 316 | 1,045 | 2,930 |
| 2018 | 2,266 | 331 | 226 | 4.62 | 441 | 1,317 | 3,856 |
| 2019 | 2,621 | 351 | 252 | 5.07 | 481 | 1,635 | 4,693 |
| 2020 | 2,924 | 433 | 364 | 7.20 | 547 | 2,115 | 5,491 |
| 2021 | 3,540 | 590 | 391 | 7.60 | 761 | 2,535 | 7,024 |
| 2022 | 3,976 | 651 | 486 | 9.48 | 620 | 2,976 | 7,603 |
| 2023 | 4,129 | 617 | 475 | 9.22 | 684 | 3,597 | 8,195 |
| 2024 | 4,050 | 227 | 10 | 0.20 | 735 | 3,462 | 7,528 |
| 2025 | 4,015 | 508 | -144 | -2.91 | 738 | 3,165 | 7,135 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Charles River Laboratories International, Inc. bietet Dienste für Wirkstoffforschung, nichtklinische Entwicklung und Sicherheitstests in den USA, Europa, Kanada, dem asiatisch-pazifischen Raum und international an.
| Employees | 18,300 |
|---|---|
| Headquarters | Wilmington, MA |
| Address | 251 Ballardvale Street, 01887 Wilmington, United States |
| Phone | 781 222 6000 |
| Website | criver.com |
| IPO Date | 23. Jun 2000 |
| ISIN | US1598641074 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Birgit Girshick | CEO & Director | 1970 |
| Michael Gunnar Knell | Corporate Senior VP & Chief Accounting Officer | 1977 |
| Joseph W. LaPlume J.D. | Corporate Executive Vice President of Corporate Development & Strategy | 1974 |
| Victoria L. Creamer | Corporate Executive VP & Chief People Officer | 1970 |
| Glenn G. Coleman CPA | Corporate Executive VP & CFO | 1968 |
| Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services | 1974 |
| Todd Spencer | Corporate Vice President of Investor Relations | – |
| Kerry Dailey | Corporate Senior VP & Chief Legal Officer | – |
| Amy E. Cianciaruso | Corporate Senior Vice President, Chief Communications Officer & Government Relations | – |
| Brian F. Bathgate Ph.D. | Corporate Senior Vice President of European Safety Assessment | 1960 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.